达格列净联合二甲双胍治疗2型糖尿病的临床研究

Clinical study on dapagliflozin combined with metformin for the treatment of type 2 diabetes mellitus

目的探讨达格列净联合二甲双胍治疗2型糖尿病的临床效果。方法选取合肥市第二人民医院2019年6月至2021年5月诊治的2型糖尿病患者100例为研究对象,采用随机数字表法分为对照组(n=50)和试验组(n=50)。对照组采用二甲双胍常规治疗,试验组采用达格列净联合二甲双胍治疗,两组疗程3个月。比较两组患者的血糖指标、血脂水平及不良反应发生情况。结果治疗后,试验组空腹血糖、餐后2 h血糖、糖化血红蛋白分别为(5.56±0.37)mmol/L、(8.32±0.23)mmol/L、(6.17±0.26)%,均低于对照组的(6.96±0.48)mmol/L、(9.58±0.39)mmol/L、(7.27±0.26)%,差异均有统计学意义(t=3.59、6.92、5.03,均P < 0.05);试验组总胆固醇、三酰甘油分别为(3.58±0.53)mmol/L、(1.25±0.26)mmol/L,均低于对照组的(4.94±0.58)mmol/L、(1.93±0.18)mmol/L,差异均有统计学意义(t=3.16、4.25,均P < 0.05)。两组不良反应发生率差异无统计学意义(P > 0.05)。结论达格列净联合二甲双胍可有效控制2型糖尿病患者血糖、血脂,且不增加不良反应。

Objective To investigate the clinical effect of dapagliflozin combined with metformin on type 2 diabetes mellitus(T2DM).Methods A total of 100 patients with T2DM who received treatment in The Second People's Hospital of Hefei from June 2019 to May 2021 were included in this study.They were randomly divided into a control group(n=50)and an experimental group(n=50).The control group was treated with metformin,and the experimental group was treated with dagglitazin combined with metformin.All patients were treated for 3 months.Blood glucose index,blood lipid level,and the incidence of adverse reactions were compared between the two groups.Results After treatment,fasting blood glucose,2-hour post-prandial blood glucose,and glycosylated hemoglobin in the experimental group were(5.56±0.37)mmol/L,(8.32±0.23)mmol/L,and(6.17±0.26)%respectively,which were significantly lower than(6.96±0.48)mmol/L,(9.58±0.39)mmol/L,and(7.27±0.26)%respectively in the control group(t=3.59,6.92,5.03,all P<0.05).The total cholesterol and triglyceride in the experimental group were(3.58±0.53)mmol/L and(1.25±0.26)mmol/L,respectively,which were significantly lower than(4.94±0.58)mmol/L and(1.93±0.18)mmol/L in the control group(t=3.16,4.25,both P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with metformin can effectively control blood glucose and blood lipid in T2DM patients without increasing adverse reactions.